LNTH News and Press, Lantheus Holdings Inc. From 05/03/21

[[AME]], [[APO]], [[ARCB]], [[ARNC]], [[ATC]], [[BEN]], [[BEP]], [[BERY]], [[BG]], [[BHC]], [[BR]], [[CMI]], [[COP]], [[CQP]], [[CRL]], [[CRSR]], [[CTLT]], [[CVLT]], [[CVS]], [[CWH]], [[D]], [[DD]], [[DEA]], [[ETN]], [[ETRN]], [[EXPD]], [[FI]], [[FSS]], [[GCP]], [[GPN]], [[HEP]], [[HSC]], [[H...

EXINI Diagnostics AB, a subsidiary of Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence (AI) solutions to Find, Fight and Follow serious medical cond...

Lantheus Holdings (LNTH) announces a strategic collaboration with Allegheny Health Network ((AHN)) for the use of its Microbubbles in Combination with ultrasound assisted gene therapy for the development of a proposed treatment for xerostomia, a lack of saliva production leading to ...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced a strategic collabo...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, to discuss its financial and operating results for the first quarter of 2021. To access the live conferen...

Bela Denes, MD Joins as Vice President of Medical Affairs Iryna Teslenko, MD, MBA Joins as Vice President of Clinical Development Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diag...

Lantheus Holdings ([[LNTH]] +9.3%) is likely to record its biggest one-day gain since April 2020 after announcing the acquisition of exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics.NTI-1309 that tar...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the...

- Statistically Significant Correlation Between Biomarker Responses and Objective Tumor Response - Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artifici...

OSPREY Phase 2/3 Results Published in the Journal of Urology CONDOR Phase 3 Results Published in Clinical Cancer Research Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics,...